| Autor: |
Otedo, AEO, Otieno, CF, Jowi, J, Oyoo, GO, Omonge, EO |
| Jazyk: |
angličtina |
| Rok vydání: |
2014 |
| Zdroj: |
East African Medical Journal; Vol 90, No 12 (2013): Supplement; S33-S39 |
| ISSN: |
0012-835X |
| Popis: |
Background: Cryptococcus meningitis is the most lethal meningitis in patients with HIV/AIDS. It is invariably fatal if not treated appropriately and promptly. In sub-Saharan Africa with the highest prevalence of HIV/AIDS, response to treatment of cryptococcal meningitis has seldom been assessed.Objective: To describe the clinical features, laboratory findings, CD4+ cell counts and clinical outcome after a two-week treatment course of patients having cryptococcal meningitis.Design: Longitudinal, prospective, consecutive entry study.Setting: Kisumu District Hospital, Nairobi Rheumatology Clinic and Mater hospital between July 2001 and May 2007.Subjects: One hundred and forty one patients with cryptococcus meningitis.Main outcome measures:CD4+cellcount,cerebrospinalfluid(CSF) biochemistry/microbiology, morbidity and mortality.Results: One hundred and forty one patients (80 males and 61 females) with cryptococcus meningitis were included. Mean age and CD4+ cell counts was 36.12 ± 9.1 years (15-75) and 66.9 ± 102.8 cells/µl (1-1058) respectively. One hundred and forty one (83%) patients had CD4 + cell counts 350 cells/µl and 22 (15.6%) patients had CD4+cell counts between 100-350 cells/µl. Ten (six males and four females) died within one week (four amphotericin B, three fluconazole, three no treatment). Eighty one patients were simultaneously initiated on HAART.Conclusion: Cryptococcal meningitis has a good clinical outcome when promptly and appropriately managed despite the low CD4+ cell count. Measures to avail amphotericin B and fluconazole at the mid level healthcare facilities must be enhanced. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
